In a report released today, Gbola Amusa from Chardan Capital maintained a Hold rating on Esperion (ESPR), with a price target of $50. The company’s shares opened today at $54.90.
Amusa noted:
“We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 18.7% and a 50.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Iovance Biotherapeutics Inc, and Catalyst Biosciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Esperion with a $94.20 average price target, a 71.6% upside from current levels. In a report released yesterday, J.P. Morgan also upgraded the stock to Hold with a $47 price target.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $60.04 million. In comparison, last year the company had a GAAP net loss of $37.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
